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Master or slave:The complex relationship of RBP2 and pRb 
The retinoblastoma protein or its regulators are altered in most human cancers. Although commonly thought of as solely a 
repressor of E2F-dependent transcription and cell cycle progression, pRb has gained notoriety in recent years as a key 
actor in cellular differentiation programs. In the June issue of Molecular Cell, Benevolenskaya et al. report that a long­
known but poorly understood pRb interactor, RBP2, acts as an inhibitor of differentiation contributing to pRb’s role as a 
coordinator of differentiation and cell cycle exit. Loss of pRb may unleash RBP2, maintaining cells in a poorly differentiat­
ed progenitor state that is prerequisite to tumor formation. 
In the course of normal development, ARID-, and Jumonji- domains; and binds similarly seen with RBP2 siRNA transfec­
cells differentiate into their specified, ter- to p107 and TATA binding protein, but its tion.Thus, inactivation of RBP2 is cytosta­
minal state and ultimately exit the cell function has remained elusive until now. tic and is sufficient for turning on 
cycle. The process of differentiation is Remarkably, knockdown of RBP2 in differentiation-associated markers, which 
thus inversely correlated with prolifera- the SAOS2 system was sufficient to block ostensibly phenocopies the effect of pRb 
tion. In the past decade, the retinoblas- proliferation and elicit the expression of reintroduction into SAOS-2 cells. Further, 
toma protein has emerged from in a myelopoiesis model of differ­
its generic tumor suppressor role entiation, pRb was shown to bind 
as a cell cycle regulator acting and colocalize with RBP2 correlat­
solely through the E2F family of ing with progression from an undif­
transcription factors and is now ferentiated to a differentiated state, 
recognized as a central inter­ thus implying a mechanism by 
preter of the proliferation-to-differ­ which pRb binds and attenuates 
entiation switch in a number of RBP2 repression of differentiation. 
tissues. In osteoblasts, for exam- In bone, pRb acts to coactivate 
ple, pRb has been shown to Runx2-mediated transcription of 
directly bind the bone “master” late markers (Thomas et al., 2001). 
transcription factor Cbfa1/Runx2 Benevolenskaya et al. report that 
and act as a transcriptional coac­ like wild-type pRb, ∆663 augments 
tivator necessary for terminal dif- Runx2-dependent transcription in 
ferentiation (Thomas et al., 2001). SAOS2 cells, and, remarkably, 
Indeed, reintroduction of pRb in knockdown of RBP2 showed a 
the RB1−/− SAOS2 osteosarcoma similar induction of the bone 
cell line is sufficient to induce reporter even in the absence of 
markers of bone differentiation added pRb. Interestingly, an addi­
and acquisition of a senescent tive effect on both the GRα and 
phenotype (Alexander and Hinds, 6OSE2 reporters was observed 
2001). Surprisingly, a pRb mutant, when wt pRb and RBP2-targeted 
RB LP ∆663, which lacks the siRNA where cotransfected. This 
canonical ability to bind and Figure 1. pRb: differentiation and proliferation may be a result of the RBP2 siRNA 
repress E2F-dependent transcrip- Proper tissue development requires a coordinated process more effectively eliminating a stoi­
tion, is capable of eliciting the of cellular differentiation and cell cycle exit. The tumor sup- chiometric excess of RBP2 in the 
pressor pRb may act as a central decision maker in thissame differentiation/senescence process. pRb’s best-known function is to block proliferation cell than is achieved solely with 
response as the wild-type protein by binding and inactivating the E2F family of transcription pRb overexpression. Alternatively, (Sellers et al., 1998). This raises factors. More recently, pRb has been reported to influence pRb may have other roles not 
the question of what sort of char- the activity of many proteins in order to achieve the switch dependent on RBP2 interaction, 
acters pRb might be associating from proliferation to differentiation. The colored arm of the but in any case, induction of 
with to accomplish this E2F-inde- schematic represents a new pathway of pRb regulation in Runx2 activity by RBP2 knock­differentiation described by Benevolenskaya et al. In thependent process. absence of a fully functional pRb, RBP2 silencing was suffi- down in the absence of pRb sug-
As reported in the June issue cient to achieve a proliferative halt and elicit a differentia- gests a wholly new model of pRb 
of Molecular Cell, Benevolenskaya tion program in a variety of cell types in culture. Further, the action in this system. In this 
et al. (2005) used the ∆663 pRb pRb/RBP2 complex augmented the expression of homeotic model, RBP2 acts to inhibit differ­
mutant in a yeast 2-hybrid screen genes (BRD2 and -8) that may prove to be a key and fertile entiation-specific genes, and pRb 
area of research. What remains unclear, however, is howto capture pRb-associated factors. does a “differentiation block” work? acts at least in part to counteract 
What surfaced from this approach this repression (Figure 1). Indeed, 
was a well-known but largely in chromatin immunoprecipitation 
uncharacterized pRb binding part- (ChIP) experiments, RBP2 was 
ner, RBP2. Identified as one of the first bone differentiation markers. Further, dif- found bound to the osteocalcin promoter, 
cellular pRb binding partners, RBP2 had ferentiation-associated transcriptional but could be displaced by pRb when 
thwarted several attempts at characteri- activation via glucocorticoid receptor introduced. Upon pRb binding of RBP2, 
zation. RBP2 is ubiquitously expressed; (GRα) was enhanced upon introduction of the repression is alleviated, and 
has a canonical LXCXE motif; PHD-, wild-type pRb, and this activation effect is pRb/Runx2 complexes then bind and 
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activate the promoter as previously 
proposed. 
Benevolenskaya et al. also investigat­
ed whether this pRb-RBP2 antagonistic 
mechanism exists in other cell types that 
are mesenchymally derived, as reintro­
duction of pRb in RB−/− cells can also pro­
mote differentiation into myoblasts and 
adipocytes (Classon and Harlow, 2002). 
Indeed, knockdown of RBP2 caused a 
proliferation block and differentiation in this 
system reminiscent of pRb restoration. 
The work of Benevolenskaya et al. 
seems to solidly confirm a role for pRb in 
differentiation that has been strongly hint­
ed at by other recent studies.The Id family 
proteins inhibit differentiation and drive 
proliferation. In particular, Id2 has been 
shown to bind to pRb and p107. It is pro­
posed that the pRb family proteins act to 
restrain Id2’s antidifferentiative function 
manifested through inhibition of the activity 
of transcription factors such Ets, Pax, and 
bHLH. Of note, p16Ink4a is a target of the 
Ets transcription factor, and many bHLH 
proteins play a significant role in differenti­
ation programs (Lasorella et al., 2001). 
More recently, it has been shown that 
the E1A-like inhibitor of differentiation 1 
(EID-1) is a pRb binding protein with a 
classic LXCXE motif that was also 
identified in a yeast two-hybrid screen 
(MacLellan et al., 2000). EID-1 overex­
pression in muscle inhibits differentiation. 
It has been shown that pRb is necessary 
for the degradation of the EID-1 complex, 
which then allows for transcriptional acti­
vation of differentiation markers (i.e., GR 
and MyoD) (Krutzfeldt et al., 2005).This is 
not a well-understood pathway, but pro­
vides another example of how pRb’s 
gene-repressive role is disassociated 
from its gene-activation role. 
When we consider transcription fac­
tors within pRb’s sphere of influence, it is 
important to consider the role of the E2F 
family of transcription factors on differen­
tiation. The activating E2Fs (1-3a) have 
been shown to turn on genes necessary 
for S phase progression, while E2F3b-5 
enforce cell cycle arrest. However, E2Fs 
have been implicated in a more direct 
role in differentiation evidenced by the 
various tissue-specific defects seen in 
different E2F knockout animals. Further, 
in adipocytes, E2Fs have been shown to 
bind C/EBP and PPAR-γ and modulate 
differentiation (reviewed in Trimarchi and 
Lees, 2002). Interestingly, recent reports 
have shown that direct E2F repression is 
necessary for keratinocyte differentiation 
(Wong et al., 2005). Given pRb’s role in 
regulating E2F family function, it is likely 
that some of pRb’s effects on differentia­
tion are mediated by the E2F family. 
These multiple functions of pRb in 
various differentiation systems point out 
the myriad changes that accompany what 
now appears to be a pRb-coordinated dif­
ferentiation and cell cycle exit program. As 
mentioned earlier, pRb directly binds to 
Runx2 to turn on genes of late differentia­
tion in bone. Recently, however, Runx2 
itself was shown to have independent 
cytostatic properties. Briefly, ectopically 
expressed Runx2 caused accumulation 
of p27Kip1, which leads to dephosphoryla­
tion of pRb and G1 cell cycle arrest, there­
by creating a feedforward loop where cell 
cycle exit promotes differentiation 
(Thomas et al., 2004). Interestingly, the 
proliferation arrest accomplished by 
RBP2 knockdown experiments in the 
RB−/− SAOS2 system by Benevolenskaya 
et al. showed an accumulation of p27Kip1, 
as well p21Cip1 and p130. However, not all 
aspects of the differentiation phenotype 
(the senescent cell morphology change) 
could be phenocopied by arresting RB−/− 
SAOS2 cells via the canonical E2F/pRb 
pathway, arguing that cell cycle arrest 
alone is insufficient to potentiate SAOS2 
cells for differentiation. 
Thus, while compelling in its potential 
to provide a global, mechanistic explana­
tion for the role of pRb in differentiation 
and the accompanying cell cycle exit, the 
work of Benevolenskaya et al. leaves 
many questions unanswered. How is the 
cell halting proliferation in the absence of 
pRb? Is RBP2 inactivation sufficient for 
turning on a global differentiation cascade, 
or is it cell-type specific? Is it a complete 
differentiation program? Is RBP2 redun­
dant to or interactive with the Id, EID-1, or 
E2F modes of differentiation induction? 
To explore the function of RBP2 more 
fully, the authors looked for other promot­
ers that RBP2 binds by using a ChIP-on­
chip (the promoter region of 10,000 
human genes) approach in a 
myelopoiesis differentiation system. They 
identified the promoters of two homeotic 
genes, BRD2 and BRD8. Intriguingly, by 
further characterizing these interactions, 
they determined that the RBP2/pRb inter­
action augments transcriptional activa­
tion of these genes. Based on the 
literature, the authors suggest that BRD2 
and -8 might be necessary for the main­
tenance of the active chromosomal 
architecture of genes necessary for dif­
ferentiation-homeostasis in postmitotic 
cells. Taken together, the data presented 
by Benevolenskaya et al. suggest a 
biphasic effect of the RBP2/pRb com­
plex: pRb binds RBP2, neutralizing its 
repression on cell type-specific genes. 
This RBP2 complex is then free to act as 
a coactivator for genes that promote sta­
ble terminal differentiation (Figure 1). 
Much more work will be needed to 
explore how this growing number pRb 
interlocutors interact in order to co­
ordinate differentiation with cell cycle 
exit. Nevertheless, the work of 
Benevolenskaya et al. highlights a grow­
ing view that cancer is not a disorder of 
proliferation but of cell differentiation 
(Harris, 2004) and that pRb is likely a 
central decision maker in this process. 
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